Sydnexis Announces FDA Advisory Committee Meeting Date to Review NDA for SYD-101 for Pediatric Progressive Myopia

Advisory Committee Meeting and Public Hearing Set for October 30, 2026

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a clinical-stage pharmaceutical company developing SYD-101, a novel low-dose atropine formulation for the treatment of pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug Administration (FDA) has scheduled an Advisory Committee meeting, including an Open Public Hearing, for October 30, 2026, to review the New Drug Application (NDA) for SYD-101. SYD-101 is currently approved in the European Union and UK, where it is licensed to Santen S.A. and marketed as Ryjunea®.

Click here to read the full story.

To access a PDF of the story click here.

Shared by Tyler Stowater, board member of Sydnexis, Inc.